Panacea Biotec (PANACEABIO) | Stock Overview & Key Data
Panacea Biotec Performance Comparison
Stock Range
Today's Range
Low: ₹400.00
High: ₹418.90
on September 26, 2025
52 Week Range
Low: ₹259.70
High: ₹581.90
on September 27, 2024
on April 30, 2025
All-Time High: ₹581.90 on April 28, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR24.9B
EPS
1.89
P/E Ratio (TTM)
216.64
Forward P/E
N/A
P/B Ratio
2.99
PEG Ratio
-1.73
Div. Yield
N/A
ROE
-1.01%
Beta
0.363
Debt to Equity
2.67
Financial Highlights
Profitability
Gross Margin
53.68%
Operating Margin
-5.74%
Profit Margin
1.88%
Returns and Earnings
Return on Assets (TTM)
-0.65%
Return on Equity (TTM)
-1.01%
EBITDA
INR-125.9M
Net Income (TTM)
INR114.8M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR99.60
Quarterly Revenue Growth (YoY)
44.10%
Quarterly Earnings Growth (YoY)
44.05%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Panacea Biotec PANACEABIO | 24.87B Small-cap | -5.33% | 2.52% | -0.88% | -8.13% | -7.93% | 41.36% | 207.84% | 112.75% |
| Biocon BIOCON | 455.97B Large-cap | -8.21% | -5.41% | -3.31% | -2.70% | -8.11% | -8.12% | 16.48% | -25.13% |
| OneSource Specialty ONESOURCE | 207.35B Large-cap | -2.78% | -3.87% | -10.63% | 4.11% | 4.67% | 4.67% | 4.67% | 4.67% |
| Dishman Carbogen DCAL | 44.90B Small-cap | -6.39% | 3.53% | 14.40% | 26.29% | -1.42% | 53.25% | 191.75% | 71.91% |
| Zota Health Care ZOTA | 44.37B Small-cap | -1.07% | 18.72% | 51.66% | 77.66% | 79.38% | 130.99% | 399.93% | 884.03% |
| 3B Blackbio 3BBLACKBIO | 11.82B Small-cap | -1.17% | -5.06% | -2.69% | -18.06% | -29.63% | 3.44% | 74.30% | 74.30% |
Ownership & Short Interest
Insider Ownership
72.65%
Institutional Ownership
0.11%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
204K
Average 90-Day Volume
188K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PANACEABIO's 52-week high and low?
- In the last 52 weeks, Panacea Biotec reached a high of ₹581.90 (on April 30, 2025) and a low of ₹259.70 (on September 27, 2024).
- What is the market cap and P/E ratio for PANACEABIO?
- Curious about Panacea Biotec's size and valuation? Its market capitalization stands at 24.87B. When it comes to valuation, the P/E ratio (trailing twelve months) is 216.64, and the forward P/E (looking ahead) is N/A.
- Does PANACEABIO pay dividends? If so, what's the yield?
- As for dividends, Panacea Biotec isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Panacea Biotec's main competitors or similar companies to consider before investing?
When looking at Panacea Biotec, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Biocon
BIOCON455.97B Healthcare Biotechnology -8.12% 16.48% OneSource Specialty
ONESOURCE207.35B Healthcare Biotechnology 4.67% 4.67% Dishman Carbogen
DCAL44.90B Healthcare Biotechnology 53.25% 191.75% Zota Health Care
ZOTA44.37B Healthcare Biotechnology 130.99% 399.93% 3B Blackbio
3BBLACKBIO11.82B Healthcare Biotechnology 3.44% 74.30% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Panacea Biotec Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Panacea Biotec's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -1.01%, the Debt to Equity ratio from the most recent quarter is 2.67, and its Gross Profit Margin stands at 53.68%.
- What is the recent revenue and earnings growth for PANACEABIO?
- Looking at Panacea Biotec's growth, its revenue over the trailing twelve months (TTM) was INR6B. Compared to the same quarter last year (YoY), quarterly revenue grew by 44.10%, and quarterly earnings saw a YoY growth of 44.05%.
- How much of PANACEABIO stock is held by insiders and institutions?
- Wondering who owns Panacea Biotec stock? Company insiders (like executives and directors) hold about 72.65% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.11%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.